Neurogene Earnings Estimate
| NGNE Stock | 17.38 0.38 2.24% |
Neurogene | Build AI portfolio with Neurogene Stock |
Neurogene Earnings Estimation Breakdown
The calculation of Neurogene's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Neurogene is estimated to be -1.0475 with the future projection ranging from a low of -1.065 to a high of -1.03. Please be aware that this consensus of annual earnings estimates for Neurogene is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.06 Lowest | Expected EPS | -1.03 Highest |
Neurogene Earnings Projection Consensus
Suppose the current estimates of Neurogene's value are higher than the current market price of the Neurogene stock. In this case, investors may conclude that Neurogene is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Neurogene's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 7 | 87.07% | -0.99 | -1.0475 | -4.1 |
Neurogene Earnings per Share Projection vs Actual
Actual Earning per Share of Neurogene refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Neurogene predict the company's earnings will be in the future. The higher the earnings per share of Neurogene, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Neurogene Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Neurogene, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Neurogene should always be considered in relation to other companies to make a more educated investment decision.Neurogene Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Neurogene's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-13 | 2025-09-30 | -1.18 | -0.99 | 0.19 | 16 | ||
2025-08-11 | 2025-06-30 | -1.11 | -1.05 | 0.06 | 5 | ||
2025-05-08 | 2025-03-31 | -1.12 | -1.08 | 0.04 | 3 | ||
2025-03-17 | 2024-12-31 | -1.1283 | -0.99 | 0.1383 | 12 | ||
2024-11-12 | 2024-09-30 | -1.22 | -1.1925 | 0.0275 | 2 | ||
2024-08-09 | 2024-06-30 | -1.05 | -1.09 | -0.04 | 3 | ||
2024-05-10 | 2024-03-31 | -1.13 | -1.0 | 0.13 | 11 | ||
2024-03-18 | 2023-12-31 | -1.17 | -1.51 | -0.34 | 29 | ||
2023-11-14 | 2023-09-30 | -0.03 | -0.4077 | -0.3777 | 1259 | ||
2023-08-16 | 2023-06-30 | -0.04 | -0.04 | 0.0 | 0 | ||
2023-05-10 | 2023-03-31 | -0.22 | -0.26 | -0.04 | 18 | ||
2023-03-16 | 2022-12-31 | -0.19 | -0.24 | -0.05 | 26 | ||
2022-11-14 | 2022-09-30 | -0.3043 | -0.24 | 0.0643 | 21 | ||
2022-08-09 | 2022-06-30 | -0.3 | -0.28 | 0.02 | 6 | ||
2022-05-09 | 2022-03-31 | -0.298 | -0.28 | 0.018 | 6 | ||
2022-03-01 | 2021-12-31 | -0.2957 | -0.28 | 0.0157 | 5 | ||
2021-11-04 | 2021-09-30 | -0.2783 | -0.28 | -0.0017 | 0 | ||
2021-08-05 | 2021-06-30 | -0.262 | -0.27 | -0.008 | 3 | ||
2021-05-12 | 2021-03-31 | -0.228 | -0.27 | -0.042 | 18 | ||
2021-03-25 | 2020-12-31 | -0.2443 | -0.22 | 0.0243 | 9 | ||
2020-11-09 | 2020-09-30 | -0.22 | -0.04 | 0.18 | 81 | ||
2020-08-12 | 2020-06-30 | -0.21 | -0.2 | 0.01 | 4 | ||
2020-05-06 | 2020-03-31 | -0.23 | -0.18 | 0.05 | 21 | ||
2020-03-12 | 2019-12-31 | -0.28 | -0.23 | 0.05 | 17 | ||
2019-11-13 | 2019-09-30 | -0.04 | -2.26 | -2.22 | 5550 | ||
2019-08-07 | 2019-06-30 | -0.05 | -0.09 | -0.04 | 80 | ||
2019-05-06 | 2019-03-31 | -0.23 | -0.09 | 0.14 | 60 | ||
2019-03-18 | 2018-12-31 | -0.79 | -0.21 | 0.58 | 73 | ||
2018-11-07 | 2018-09-30 | -0.21 | -0.64 | -0.43 | 204 | ||
2018-08-08 | 2018-06-30 | -0.59 | 0.12 | 0.71 | 120 | ||
2018-05-08 | 2018-03-31 | -0.66 | -0.62 | 0.04 | 6 | ||
2018-03-12 | 2017-12-31 | -0.57 | -0.69 | -0.12 | 21 | ||
2017-11-08 | 2017-09-30 | -0.59 | -0.5 | 0.09 | 15 | ||
2017-08-08 | 2017-06-30 | -0.51 | -0.59 | -0.08 | 15 | ||
2017-05-09 | 2017-03-31 | -0.51 | -0.36 | 0.15 | 29 | ||
2017-03-10 | 2016-12-31 | -0.51 | -0.48 | 0.03 | 5 | ||
2016-11-09 | 2016-09-30 | -0.58 | -0.46 | 0.12 | 20 | ||
2016-08-04 | 2016-06-30 | -0.41 | -0.63 | -0.22 | 53 | ||
2016-05-10 | 2016-03-31 | -0.35 | -0.63 | -0.28 | 80 | ||
2016-03-14 | 2015-12-31 | -0.37 | -0.39 | -0.02 | 5 | ||
2015-11-10 | 2015-09-30 | -0.45 | -0.26 | 0.19 | 42 | ||
2015-08-06 | 2015-06-30 | -0.56 | -0.43 | 0.13 | 23 | ||
2015-05-12 | 2015-03-31 | -0.81 | -0.44 | 0.37 | 45 | ||
2015-03-03 | 2014-12-31 | -0.76 | -0.6 | 0.16 | 21 | ||
2014-11-10 | 2014-09-30 | -0.45 | -0.78 | -0.33 | 73 |
About Neurogene Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Neurogene earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Neurogene estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Neurogene fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -236.1 M | -247.9 M | |
| Earnings Yield | (0.22) | (0.20) | |
| Price Earnings Ratio | (4.81) | (5.05) | |
| Price Earnings To Growth Ratio | (0.09) | (0.10) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Will Biotechnology sector continue expanding? Could Neurogene diversify its offerings? Factors like these will boost the valuation of Neurogene. Anticipated expansion of Neurogene directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurogene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Neurogene requires distinguishing between market price and book value, where the latter reflects Neurogene's accounting equity. The concept of intrinsic value - what Neurogene's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neurogene's price substantially above or below its fundamental value.
It's important to distinguish between Neurogene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurogene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neurogene's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.